tiprankstipranks
Advertisement
Advertisement

AOTI Publishes 2025 Annual Report and Sets May 2026 AGM in London

Story Highlights
  • AOTI, Inc. develops home-based wound care technology, notably TWO2 therapy, with strong global regulatory backing.
  • The company has published its 2025 annual report and scheduled its 2026 AGM in London, inviting proxy voting.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
AOTI Publishes 2025 Annual Report and Sets May 2026 AGM in London

Meet Samuel – Your Personal Investing Prophet

AOTI, Inc. ( (GB:AOTI) ) has issued an announcement.

AOTI, Inc., a home-focused medical technology group dedicated to more durable wound healing and amputation prevention, develops and markets its patented TWO2 Topical Wound Oxygen therapy worldwide. The company’s solutions target chronic conditions such as diabetic foot ulcers, helping reduce healthcare costs and improving patients’ quality of life through clinically validated, home-administered treatment backed by major regulatory approvals.

AOTI has released its 2025 Annual Report and Financial Statements and the 2026 Notice of Annual General Meeting, which will be made available electronically on its website for shareholders. The AGM is scheduled for 21 May 2026 in London, with shareholders and holders of Depositary Interests encouraged to vote on resolutions by proxy, underscoring standard corporate governance and engagement with its investor base.

Spark’s Take on AOTI Stock

According to Spark, TipRanks’ AI Analyst, AOTI is a Neutral.

The score is primarily constrained by ongoing losses and weak cash flow sustainability despite strong revenue growth and improved margins. Technicals are supportive but show signs of being stretched, and valuation is pressured by negative earnings with no dividend support.

To see Spark’s full report on AOTI stock, click here.

More about AOTI, Inc.

AOTI, Inc. is a medical technology group based in Oceanside, California and Galway, Ireland, specializing in innovative therapies for severe and chronic wounds. Its patented non-invasive Topical Wound Oxygen (TWO2) therapy is designed for home use and has shown strong clinical and real-world evidence in reducing diabetic foot ulcer recurrence, hospitalizations, and amputations, supported by multiple international regulatory clearances and positive health technology assessments.

Average Trading Volume: 28,079

Technical Sentiment Signal: Hold

Current Market Cap: £40.95M

Find detailed analytics on AOTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1